Compare SRRK & MC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRRK | MC |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 5.3B |
| IPO Year | 2018 | 2014 |
| Metric | SRRK | MC |
|---|---|---|
| Price | $47.62 | $73.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 9 |
| Target Price | $51.20 | ★ $77.88 |
| AVG Volume (30 Days) | ★ 1.0M | 885.0K |
| Earning Date | 02-26-2026 | 02-04-2026 |
| Dividend Yield | N/A | ★ 3.63% |
| EPS Growth | N/A | ★ 63.44 |
| EPS | N/A | ★ 3.15 |
| Revenue | N/A | ★ $1,516,796,000.00 |
| Revenue This Year | N/A | $19.40 |
| Revenue Next Year | $20,029.43 | $15.63 |
| P/E Ratio | ★ N/A | $22.76 |
| Revenue Growth | N/A | ★ 26.98 |
| 52 Week Low | $22.71 | $47.00 |
| 52 Week High | $49.82 | $82.89 |
| Indicator | SRRK | MC |
|---|---|---|
| Relative Strength Index (RSI) | 53.53 | 52.65 |
| Support Level | $44.10 | $68.94 |
| Resistance Level | $49.82 | $76.87 |
| Average True Range (ATR) | 2.35 | 2.89 |
| MACD | -0.01 | -0.47 |
| Stochastic Oscillator | 45.47 | 53.06 |
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.
Moelis & Co is an independent investment bank that provides strategic and financial advice to a diverse client base, including corporations, financial sponsors, governments, and sovereign wealth funds. The company assists its clients in achieving their strategic goals by offering comprehensive, globally integrated financial advisory services across all industry sectors. It also advises clients on their critical decisions, including mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. it generates revenue from advisory transactions. The firm derives a majority of its revenue from the United States followed by Europe and the rest of the World.